Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > EDIT Editas Medicine > Detailed Quotes

EDIT Editas Medicine

Watchlist
10.410
+0.520+5.26%
Close  02/01 16:00 ET
10.580
+0.170+1.63%
Post Mkt Price 02/01 19:27 ET
High
10.620
Open
10.300
Turnover
24.86M
Low
9.783
Pre Close
9.890
Volume
2.44M
Market Cap
715.82M
P/E(TTM)
Loss
52wk High
21.595
Shares
68.76M
P/E(Static)
Loss
52wk Low
7.705
Float Cap
713.16M
Bid/Ask %
0.00%
Historical High
99.950
Shs Float
68.51M
Volume Ratio
1.33
Historical Low
7.705
Dividend TTM
--
Div Yield TTM
--
P/B
1.73
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.56%
Amplitude
8.46%
Avg Price
10.205
Lot Size
1
Float Cap
713.16M
Bid/Ask %
0.00%
Historical High
99.950
Shs Float
68.51M
Volume Ratio
1.33
Historical Low
7.705
Dividend TTM
--
P/B
1.73
Dividend LFY
--
Turnover Ratio
3.56%
Amplitude
8.46%
Avg Price
10.205
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
CEO: Mr. James C. Mullen
Market: NASDAQ
Listing Date: 02/03/2016
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist